{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:23:50Z","timestamp":1792686230376,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010724","name":"Health System Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010724","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Asia"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jacasi.2024.10.027","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T14:43:52Z","timestamp":1737470632000},"page":"191-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"P2","title":["The COOL-AF Phase 2 Registry"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8684-2361","authenticated-orcid":false,"given":"Rungroj","family":"Krittayaphong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjbordin","family":"Winijkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Voravut","family":"Rungpradubvong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8396-0511","authenticated-orcid":false,"given":"Sirin","family":"Apiyasawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3986-1951","authenticated-orcid":false,"given":"Arintaya","family":"Phrommintikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thoranis","family":"Chantrarat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komsing","family":"Methavigul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ply","family":"Chichareon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pattarapong","family":"Makarawate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wattana","family":"Wongtheptien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yodying","family":"Kaolawanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacasi.2024.10.027_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1747493019897870","article-title":"Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge","volume":"16","author":"Lippi","year":"2021","journal-title":"Int J Stroke"},{"issue":"2","key":"10.1016\/j.jacasi.2024.10.027_bib2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/ehjqcco\/qcaa093","article-title":"Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs","volume":"8","author":"Burdett","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.jacasi.2024.10.027_bib3","first-page":"163","article-title":"Three-year outcomes of patients with non-valvular atrial fibrillation: the COOL-AF registry","volume":"20","author":"Krittayaphong","year":"2023","journal-title":"J\u00a0Geriatr Cardiol"},{"key":"10.1016\/j.jacasi.2024.10.027_bib4","article-title":"Atrial fibrillation: stroke prevention","volume":"37","author":"Chao","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jacasi.2024.10.027_bib5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12872-018-0911-4","article-title":"Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study","volume":"18","author":"Krittayaphong","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jacasi.2024.10.027_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/fca-2020-0014","article-title":"GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke","volume":"17","author":"Bassand","year":"2021","journal-title":"Future Cardiol"},{"key":"10.1016\/j.jacasi.2024.10.027_bib7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ihj.2020.11.152","article-title":"One-year clinical outcome of patients with nonvalvular atrial fibrillation: insights from KERALA-AF registry","volume":"73","author":"Bahuleyan","year":"2021","journal-title":"Indian Heart J"},{"key":"10.1016\/j.jacasi.2024.10.027_bib8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.beha.2013.07.009","article-title":"Disadvantages of VKA and requirements for novel anticoagulants","volume":"26","author":"Shameem","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jacasi.2024.10.027_bib9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ijcard.2016.08.236","article-title":"Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry","volume":"223","author":"Oh","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacasi.2024.10.027_bib10","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00228-017-2265-8","article-title":"The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients","volume":"73","author":"Wattanachai","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jacasi.2024.10.027_bib11","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ijcard.2014.11.182","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal","volume":"180","author":"Lip","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacasi.2024.10.027_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2024.10.027_bib13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2024.10.027_bib14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1055\/s-0041-1739411","article-title":"2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: executive summary","volume":"122","author":"Chao","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacasi.2024.10.027_bib15","doi-asserted-by":"crossref","first-page":"O61","DOI":"10.1093\/eurheartj\/suaa181","article-title":"Atrial fibrillation in low- and middle-income countries: a narrative review","volume":"22","author":"Santos","year":"2020","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.jacasi.2024.10.027_bib16","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.hlc.2019.02.187","article-title":"Cost-effectiveness analysis of non-vitamin K antagonist oral anticoagulants versus warfarin in Thai patients with non-valvular atrial fibrillation","volume":"29","author":"Dilokthornsakul","year":"2020","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.jacasi.2024.10.027_bib17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5334\/gh.774","article-title":"NOACs Added to WHO's Essential Medicines List: recommendations for future policy actions","volume":"15","author":"Di Cesare","year":"2020","journal-title":"Glob Heart"},{"key":"10.1016\/j.jacasi.2024.10.027_bib18","article-title":"Understanding the global measurement of willingness to pay in health","volume":"8","author":"McDougall","year":"2020","journal-title":"J\u00a0Mark Access Health Policy"},{"key":"10.1016\/j.jacasi.2024.10.027_bib19","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"10.1016\/j.jacasi.2024.10.027_bib20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","volume":"66","author":"Hicks","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2024.10.027_bib21","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"72","author":"Thygesen","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2024.10.027_bib22","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A\u00a0method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacasi.2024.10.027_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7594","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"350","author":"Collins","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jacasi.2024.10.027_bib24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7326\/M18-1376","article-title":"PROBAST: a tool to assess the risk of bias and applicability of prediction model studies","volume":"170","author":"Wolff","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacasi.2024.10.027_bib25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12916-019-1466-7","article-title":"Calibration: the Achilles heel of predictive analytics","volume":"17","author":"Van Calster","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.jacasi.2024.10.027_bib26","article-title":"External validation of clinical prediction models using big datasets from e-health records or IPD meta-analysis: opportunities and challenges","volume":"353","author":"Riley","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jacasi.2024.10.027_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1175\/1520-0493(1950)078<0001:VOFEIT>2.0.CO;2","article-title":"Monthly weather review: verification of forecasts expressed in terms of probability","volume":"78","author":"Brier","year":"1950","journal-title":"Monthly Weather Review"},{"key":"10.1016\/j.jacasi.2024.10.027_bib28","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1093\/ije\/dyr013","article-title":"Use of reclassification for assessment of improved prediction: an empirical evaluation","volume":"40","author":"Tzoulaki","year":"2011","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jacasi.2024.10.027_bib29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41512-019-0064-7","article-title":"A\u00a0simple, step-by-step guide to interpreting decision curve analysis","volume":"3","author":"Vickers","year":"2019","journal-title":"Diagn Progn Res"},{"key":"10.1016\/j.jacasi.2024.10.027_bib30","article-title":"Calculating the sample size required for developing a clinical prediction model","volume":"368","author":"Riley","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jacasi.2024.10.027_bib31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/heartjnl-2016-309832","article-title":"Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation","volume":"103","author":"Camm","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.jacasi.2024.10.027_bib32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1253\/circj.CJ-18-0655","article-title":"Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan- Insights From GARFIELD-AF","volume":"83","author":"Koretsune","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.jacasi.2024.10.027_bib33","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2024.10.027_bib34","first-page":"242","article-title":"Rate of anticoagulant use, and factors associated with not prescribing anticoagulant in older Thai adults with non-valvular atrial fibrillation: a multicenter registry","volume":"16","author":"Krittayaphong","year":"2019","journal-title":"J\u00a0Geriatr Cardiol"},{"key":"10.1016\/j.jacasi.2024.10.027_bib35","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s40273-023-01276-5","article-title":"Cost effectiveness of strategies to manage atrial fibrillation in middle- and high-income countries: a systematic review","volume":"41","author":"Okafor","year":"2023","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.jacasi.2024.10.027_bib36","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1253\/circj.CJ-17-0071","article-title":"Sex-related differences in the clinical events of patients with atrial fibrillation- the Fushimi AF Registry","volume":"81","author":"Ogawa","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.jacasi.2024.10.027_bib37","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/bmj.p736","article-title":"RCTs and real world evidence are complementary, not alternatives","volume":"381","author":"Morales","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.jacasi.2024.10.027_bib38","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1001\/jama.2023.4855","article-title":"Randomized trials vs real-world evidence: how can both inform decision-making?","volume":"329","author":"Sheldrick","year":"2023","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.jacasi.2024.10.027_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph191811191","article-title":"Rural-urban differences in use of rhythm control therapies in patients with incident atrial fibrillation: a Finnish Nationwide Cohort Study","volume":"19","author":"Teppo","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jacasi.2024.10.027_bib40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.hrthm.2017.10.019","article-title":"Urban-rural differences in mortality for atrial fibrillation hospitalizations in the United States","volume":"15","author":"O'Neal","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacasi.2024.10.027_bib41","article-title":"Rurality and atrial fibrillation: patient perceptions of barriers and facilitators to care","volume":"12","author":"Mann","year":"2023","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.jacasi.2024.10.027_bib42","first-page":"1698","article-title":"Poor time in therapeutic range control is associated with adverse clinical outcomes in patients with non-valvular atrial fibrillation: a report from the nationwide COOL-AF Registry","volume":"9","author":"Krittayaphong","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jacasi.2024.10.027_bib43","first-page":"612","article-title":"Optimal INR level in elderly and non-elderly patients with atrial fibrillation receiving warfarin: a report from the COOL-AF nationwide registry in Thailand","volume":"17","author":"Krittayaphong","year":"2020","journal-title":"J\u00a0Geriatr Cardiol"},{"key":"10.1016\/j.jacasi.2024.10.027_bib44","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2147\/CIA.S302389","article-title":"Age-related clinical outcomes of patients with non-valvular atrial fibrillation: insights from the COOL-AF Registry","volume":"16","author":"Krittayaphong","year":"2021","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.jacasi.2024.10.027_bib45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1055\/s-0043-1772773","article-title":"Non-vitamin K antagonist oral anticoagulant, warfarin, and ABC pathway adherence on hierarchical outcomes: win ratio analysis of the COOL-AF Registry","volume":"124","author":"Treewaree","year":"2024","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacasi.2024.10.027_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282455","article-title":"Causes of death of patients with non-valvular atrial fibrillation in Asians","volume":"18","author":"Krittayaphong","year":"2023","journal-title":"PloS One"},{"key":"10.1016\/j.jacasi.2024.10.027_bib47","article-title":"Impact of achieving blood pressure targets and high time in therapeutic range on clinical outcomes in patients with atrial fibrillation adherent to the atrial fibrillation better care pathway: a report from the COOL-AF Registry","volume":"12","author":"Krittayaphong","year":"2023","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacasi.2024.10.027_bib48","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jamacardio.2016.0529","article-title":"Differences in clinical and functional outcomes of atrial fibrillation in women and men: two-year results from the ORBIT-AF Registry","volume":"1","author":"Piccini","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacasi.2024.10.027_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191592","article-title":"Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation","volume":"13","author":"Bassand","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.jacasi.2024.10.027_bib50","first-page":"260","article-title":"Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry","volume":"61","author":"Akao","year":"2013","journal-title":"J\u00a0Cardiol"},{"key":"10.1016\/j.jacasi.2024.10.027_bib51","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/eurheartj\/ehn139","article-title":"Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation","volume":"29","author":"Nieuwlaat","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2024.10.027_bib52","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/europace\/eut373","article-title":"A\u00a0prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry","volume":"16","author":"Lip","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.jacasi.2024.10.027_bib53","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1093\/europace\/euab327","article-title":"Prognosis and treatment of atrial fibrillation in Asian cities: 1-year review of the Asia-Pacific Heart Rhythm Society Atrial Fibrillation Registry","volume":"24","author":"Tse","year":"2022","journal-title":"Europace"}],"container-title":["JACC: Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374724004708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374724004708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:31:53Z","timestamp":1762644713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772374724004708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2772374724004708"],"URL":"https:\/\/doi.org\/10.1016\/j.jacasi.2024.10.027","relation":{},"ISSN":["2772-3747"],"issn-type":[{"value":"2772-3747","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The COOL-AF Phase 2 Registry","name":"articletitle","label":"Article Title"},{"value":"JACC: Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacasi.2024.10.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}